Inhibition of farnesyl protein transferase by new farnesyl phosphonate derivatives of phenylalanine

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 12, 1996, Pages 1291-1296

  Lamothe, M ^a   Perrin, D ^a   Blotieres D ^b   Leborgne, M ^a   Gras, S ^a   Bonnet, D ^b   Hill, B T ^a   Halazy, S ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; METHYLPHOSPHONIC ACID; PHENYLALANINE DERIVATIVE; PHENYLALANINE METHYL ESTER; PHOSPHONIC ACID DERIVATIVE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; CATTLE; COLON CANCER; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; NONHUMAN; ONCOGENE RAS; PANCREAS CANCER; PRENYLATION; PROTEIN PROCESSING; RAT; SIGNAL TRANSDUCTION; TUMOR GROWTH;

BOS TAURUS; BOVINAE; STAPHYLOCOCCUS PHAGE 3A;

EID: 0030011713     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00238-7     Document Type: Article

References (36)

1. a) Hall, A. Science 1990, 249, 635.
2. b) Boguski, M.S.; Mc Cormick, F. Nature 1993, 366, 643.
3. c) Bos, J.L. Eur. J. Cancer 1995, 31A, 1051.
4. a) Barbacid M. Ann. Rev. Biochem. 1987, 56, 779.
5. b) Bos, J.L. Cancer Res. 1989, 49, 4682.
6. Lowy, D.R.; Willumsen, B.M. Nature 1989, 341, 384.
7. a) Casey, P.J.; Solsky, P.A.; Der, C.J.; Buss, J.E. Proc. Nat. Acad Sci USA 1989, 86, 8323.
8. b) Cox, A.; Der, C.J. Curr. Opin. Cell. Biol. 1992, 4, 1008.
9. Reiss, Y.; Goldstein, J.L.; Seabra, M.C.; Casey, P.Y.; Brown, M.S. Cell 1990, 62, 81.
10. a) Tamanoï, F. TIBS 1993, 18, 349.
11. b) Omura, S.; Takeshima, H. Drugs of the Future 1994, 19, 751.
12. c) Gibbs, J.B.; Oliff, A.; Kohl, N.B. Cell 1994, 77, 175.
13. d) Hamilton, A.D.; Sebti, S.M. DN & P. 1995, 8, 138.
14. a) Kohl, N.B. et al. Nature Medicine 1995, 7, 792.
15. b) Kohl, N.E. et al. Proc. Nat. Acad. Sci. USA 1994, 91, 9141.
16. Graham, S.L. Exp. Opin. Ther. Patents 1995, 5, 1269.
17. a) Bhide, R.S.; Patel, D. V.; Patel, M.M.; Robinson, S.P.; Hunihan, L.W.; Gordon, E.M. Bioorg. Med. Chem. Lett. 1994, 4, 17.
18. b) Patel, D.V.; Gordon, E.M.; Schmidt R.J.; Weller, H.N.; Young, M.G.; Zahler, R.; Barbacid, M.; Carboni, J.M.; Gullo-Brown, J.L.; Hunihan, L.; Ricca, C.; Robinson, S.; Seizinger, B.R.; Tuomari, A.V.; Manne, V. J. Med. Chem. 1995, 38, 435.
19. c) Manne, V.; Yan, N.; Carboni, J.M.; Tuomari, A.V.; Ricca, C.S.; Gullo-Brown, J.; Andahazy, M.L.; Schmidt, R.J.; Patel, D; Zahler, R.; Weinmann, R.; Der, C.J.; Cox, A.D.; Hunt, J.T.; Gordon, E.M.; Barbacid, M.; Seizinger, B. Oncogene 1995, 10, 1763.
20. Manne, V.; Ricca, C.S.; Gullo-Brown, J.; Tuomari, A.V.; Yan, N.; Patel, D.; Schmidt, R.; Lynch, M.J.; Ciosek, C.P.; Carboni, J.M.; Robinson, S.; Gordon, E.M.; Barbacid, M.; Seizinger, B.R.; Biller, S.A. Drug Dev. Res. 1995, 34, 121.
21. a) Pompliano, D.L.; Rands, E.; Schaber, M.D.; Mosser, S.D.; Anthony, N.J.; Gibbs, J.B. Biochemistry 1992, 31, 3800.
22. b) Gibbs, J.B.; Pompliano, D.L.; Mosser, S.D.; Rondo, E.; Lingham, R.B.; Singh, S.B.; Scolnick, E.M.; Kohl, N.E.; Oliff, A. J. Biol. Chem. 1993, 268, 7617.
23. Patel, D.V.; Schmidt, R.J.; Biller, S.A.; Gordon, E.M.; Robinson, S.S.; Manne, V. J. Med. Chem. 1995, 38, 2906.
24. Abe, I; Tomesch, J.C.; Wattanasin, S.; Prestwich, G.D. Nat. Prod. Rep. 1994, 11, 279.
25. Ciosek, C.P.; Magnon, D.R.; Harrity, T.W.; Logan, J.V.; Dickson, J.K.; Gordon, E.M.; Hamilton, K.A.; Jolibois, K.G.; Kunselman, L.K.; Lawrence, R.M.; Mookhtiar, K.A.; Rich, L.C.; Slusarchyk, D.A.; Sulsky, R.B.; Biller, S.A. J. Biol. Chem. 1993, 268, 24832.
26. All new compounds have been fully characterised by CHN analysis, IR, MS and NMR spectra. Compounds 3a-3g have been isolated as mixtures of epimers at the carbon center next to the phosphoryl and/or carboxyl groups. In the case of compound 3a, the epimers at the diethylester precursor level have been separated but spontaneous epimerization was observed upon deprotection.
27. Janecki, T.; Bodalski, R. Tetrahedron Lett. 1991, 32, 6231.
28. Trost, B. M.; Verhoeven, T. R. J. Amer. Chem. Soc. 1980, 102, 4730.
29. FPT was partially purified by ion exchange chromatography on a Hi-Trap Q sepharose column from bovine brain according to a) Reiss, Y.; Goldstein, J.L.; Seabra, M.C.; Casey, P.J.; Brown, M.S. Cell 1990, 62, 81.
30. b) Moores, S.L.; Schaber, M.D.; Mosser S.D.; Rands, E.; O'Hara, M.B.; Garsky, V.M.; Marshall, M.S.; Pompliano, D.L.; Gibbs, J.B. J. Biol. Chem. 1991, 268, 14603. FPT activity was measured by fluorimetry using 2μM dansyl-GCVLS and 2μM FPP as described by Pompliano, D.L.; Gomez, R.P.; Anthony, N.J. J. Amer. Chem. Soc. 1992, 114, 7945.
31. b) Moores, S.L.; Schaber, M.D.; Mosser S.D.; Rands, E.; O'Hara, M.B.; Garsky, V.M.; Marshall, M.S.; Pompliano, D.L.; Gibbs, J.B. J. Biol. Chem. 1991, 268, 14603. FPT activity was measured by fluorimetry using 2μM dansyl-GCVLS and 2μM FPP as described by Pompliano, D.L.; Gomez, R.P.; Anthony, N.J. J. Amer. Chem. Soc. 1992, 114, 7945.
32. SS activity was determined using 0.55 μM of 3H-FPP according to the method described by Dufresnes, C.; Wilson, K.E.; Singh, S.B.; Zink, D.L.; Bergstrom, J.D.; Rew, D.; Polishook, J.D.; Meinz, M.; Huang, L.; Silverman, K.C.; Lingham, R.B.; Mojena, M.; Cascales, C.; Pelaez, F.; Gibbs, J.B. J. Nat. Products 1993, 56, 1923.
33. a) Starrett, J.E.; Tortolani, D.R.; Hitchcock, M.J.; Martin, J.C.; Mansuri, M.M. Antiviral Res. 1992, 19, 267.
34. b) De Lombaert, S.; Singh, K; Blanchard, L.; Soliman, V.F. Bioorg. Med. Chem. Lett. 1994, 4, 899.
35. c) Dickson, J.K.; Biller, S.A.; Magnin, D.R.; Petrillo, E.W.; Hillyer, J.W.; Hsieh, D.C.; Lan, S.-J.; Rinehart, J.K.; Gregg, J.W.; Harrity, T.W.; Jolibois, K.G.; Kalinowski, S.S.; Kunselman, L.K.; Mookhtiar, K.A.; Ciosek, C.P. J. Med. Chem. 1996, 39, 661.
36. For example, BMS-188494 which is the bis(pivaloyloxy-methyl) ester prodrug of the phosphonic acid BMS-187745 (a potent SS inhibitor) is an orally active hypocholesterolemic agent which has now entered phase II clinical trials (Gregg, R. E. XII International Symposium on Drugs Affecting Lipid Metabolism Houston, TX, Nov. 1995).